Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued access study for pediatric participants completing prior Gilead HIV treatment trials
2024-000521-40Phase 4
- Sponsor
- Gilead Sciences
- Start
- Jul 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir, emtricitabine, tenofovir alafenamide, elvitegravir, cobicistat and 4 more in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Primary endpoint: Number of eligible participants who have received access to the study drug(s) in the study.
02
Drugs
bictegraviremtricitabinetenofovir alafenamideelvitegravircobicistat
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-000521-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000521-40.